login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
SEAGEN INC (SGEN) Stock News
USA
- NASDAQ:SGEN -
US81181C1045
-
Common Stock
228.74
USD
-0.16 (-0.07%)
Last: 12/13/2023, 8:12:24 PM
228.95
USD
+0.21 (+0.09%)
After Hours:
12/13/2023, 8:12:24 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
SGEN Latest News, Press Relases and Analysis
All
Press Releases
a year ago - By: Bloomberg
- Mentions:
PFE
MRK
Seagen’s Ex-CEO Starts Company to Develop Drug Tackling Wide Range of Cancers
a year ago - By: Bloomberg
- Mentions:
PFE
Pfizer to ‘Catch Our Breath’ on Deals After $43 Billion Purchase
2 years ago - By: Bloomberg
- Mentions:
PFE
Biotech Rally Gets $100 Billion M&A Lift With More Deals to Come
2 years ago - By: InvestorPlace
- Mentions:
NVDA
PFE
BWA
LI
...
3 Steal-of-a-Deal Stocks to Snap Up Right Now
2 years ago - By: InvestorPlace
- Mentions:
PFE
INCY
EXEL
3 Pharma Stocks Could Be the Pills Your Portfolio Needs
2 years ago - By: Benzinga
- Mentions:
PFE
How To Earn $500 A Month From Pfizer Stock
2 years ago - By: Benzinga
Looking Into Seagen's Recent Short Interest
2 years ago - By: InvestorPlace
- Mentions:
GNRC
SNOW
SE
AMZN
...
Get Rich Quick with These 7 Growth Stocks to Buy Now
2 years ago - By: InvestorPlace
- Mentions:
PFE
PM
BMY
NEM
...
7 Dividend Stocks to Buy at a 52-Week Low
2 years ago - By: InvestorPlace
- Mentions:
PFE
Pfizer’s 2024 Comeback: A Dividend Gem in the Pharma Market
2 years ago - By: Seeking Alpha
- Mentions:
PFE
Pfizer Q4 results in focus amid gloomy outlook (NYSE:PFE)
2 years ago - By: Seeking Alpha
- Mentions:
PFE
AZN
Pfizer loses Enhertu patent dispute with Daiichi (NYSE:PFE)
2 years ago - By: Bloomberg
- Mentions:
PFE
As Pfizer’s Star Power Fades, CEO Pledges Comeback on Cancer Drugs
2 years ago - By: InvestorPlace
- Mentions:
PFE
AMC
WBA
3 Stocks That Are About to Get Absolutely Crushed
2 years ago - By: BusinessInsider
- Mentions:
PFE
Pfizer's 2030 Vision Bolstered By Seagen Deal, Analyst Cuts Price Target Amid Conservative 2024 Forecast
2 years ago - By: Seeking Alpha
- Mentions:
PFE
Pfizer closes Seagen acquisition (NYSE:PFE)
2 years ago - By: The Motley Fool
- Mentions:
PFE
MRK
Pfizer's 2024 Outlook Disappointed Wall Street, But Where Will the Stock Be in 5 Years?
2 years ago - By: InvestorPlace
- Mentions:
NVDA
CVX
HESS
PFE
...
3 Sleepy Stocks Ready to Wake up in 2024
2 years ago - By: Investor's Business Daily
- Mentions:
PFE
BNTX
MRNA
Pfizer Stock Tumble Steepens As Seagen Guidance Update Disappoints
2 years ago - By: Seeking Alpha
- Mentions:
PFE
Pfizer stock slips as 2024 guidance disappoints (NYSE:PFE)
2 years ago - By: Seeking Alpha
- Mentions:
CPRI
TPR
PFE
Capri Holdings gains amid report on China review of Tapestry deal (NYSE:CPRI)
2 years ago - By: Bloomberg
- Mentions:
PFE
Pfizer to Close $43 Billion Seagen Acquisition After FTC Nod
2 years ago - By: Seeking Alpha
- Mentions:
PFE
AMGN
HZNP
Pfizer to close Seagen buyout this week as regulatory reviews complete (NYSE:PFE)
2 years ago - By: Seagen Inc.
ADCETRIS® (brentuximab vedotin) Plus Novel Immunotherapy Combination Delivers 100% Progression Free Survival at 12 months in Phase 2 Trial of Patients with Early Stage Classical Hodgkin Lymphoma
2 years ago - By: InvestorPlace
- Mentions:
T
PFE
LMT
3 Blue-Chip Stocks Set to Make a Comeback in 2024
2 years ago - By: Seeking Alpha
- Mentions:
MRK
Seagen's breast cancer drug shows positive results in combination therapy trial
2 years ago - By: Seagen Inc.
TUKYSA® (tucatinib) in Combination with Antibody-Drug Conjugate ado-Trastuzumab Emtansine Improves Progression-Free Survival in Patients with Previously Treated HER2-Positive Metastatic Breast Cancer
Please enable JavaScript to continue using this application.